Cardiovascular & Renal Drugs Advisory Committee will discuss nesiritide for treatment of acute congestive heart failure May 25. Scios will present data from the 498-patient Vasodilation in the Management of Acute Congestive heart failure trial begun in October 1999. FDA found the agent "non-approvable" and requested further study in April 1999. Scios submitted the amended NDA Jan. 10. The meeting will be held at the National Institutes of Health Masur Auditorium in Bethesda, Md. beginning at 9 a.m. The committee will review Pfizer's Cardura (doxazosin) May 24 beginning at 8:30 a.m. (1"The Pink Sheet" April 9, p. 31)
You may also be interested in...
FDA's Cardiovascular & Renal Drugs Advisory Committee is expected to discuss limiting Pfizer's Cardura (doxazosin) to second-line treatment for hypertension May 24.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials